SALT LAKE CITY, Sept. 30, 2026 (GLOBE NEWSWIRE) — Medallion Bank (Nasdaq: MBNKO), an FDIC-insured bank providing consumer loans for the purchase of recreational vehicles, boats, and home improvements, along with loan origination services to fintech strategic partners, announced today that it has closed a public offering of 2,200,000 additional shares of its Fixed-Rate Reset Non-Cumulative Perpetual Preferred Stock, Series G, par value $1.00 per share, with a liquidation amount of $25 per share (the “Series G Preferred Stock”) and an aggregate liquidation amount of $55 million. The offering priced on September 23, 2026. The underwriters have also been granted a 30-day option to purchase up to an additional 330,000 shares of the Series G Preferred Stock solely to cover over-allotments, if any.

Medallion Bank’s Series G Preferred Stock is traded on the Nasdaq Capital Market under the ticker symbol “MBNKO.” Medallion Bank remains a wholly owned subsidiary of Medallion Financial after the completion of the offering.

Medallion Bank intends to use the net proceeds from this offering for general corporate purposes, which may include, among other things, redeeming some or all of its outstanding Senior Series E Non-Cumulative Perpetual Preferred Stock (the “Series E Preferred Stock”), subject to the prior approval of the Federal Deposit Insurance Corporation.

Piper Sandler & Co., Lucid Capital Markets, LLC, Muriel Siebert & Co., LLC, A.G.P. / Alliance Global Partners, and Ladenburg Thalmann & Co. Inc. are acting as joint book-running managers. William Blair & Company, L.L.C., InspereX LLC, B. Riley Securities, Inc., and Clear Street LLC are acting as lead managers.

The offering of the Medallion Bank’s Series G Preferred Stock was exempt from the registration requirements of the Securities Act of 1933 pursuant to Section 3(a)(2) of that Act and was made only by means of an offering circular. This press release is for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction. The securities are neither insured nor approved by the Federal Deposit Insurance Corporation or any other Federal or state regulatory body.

The final offering circular relating to the offering is available at medallionbankoffering.com. In addition, copies of the final offering circular may also be obtained from: Piper Sandler & Co.; Attn: Debt Capital Markets, 1251 Avenue of the Americas, 6th Floor, New York, 10020, or by email at fsg-dcm@psc.com.

About Medallion Bank

Medallion Bank specializes in providing consumer loans for the purchase of recreational vehicles, boats, and home improvements, along with loan origination services to fintech strategic partners. The Bank works directly with thousands of dealers, contractors and financial service providers serving their customers throughout the United States. Medallion Bank is a Utah-chartered, FDIC-insured industrial bank headquartered in Salt Lake City and is a wholly owned subsidiary of Medallion Financial Corp.

For more information, visit www.medallionbank.com

This press release contains “forward-looking statements”, which reflect Medallion Bank’s current views with respect to future events and which address matters that are, by their nature, inherently uncertain and beyond Medallion Bank’s control. These statements are often, but not always, made through the use of words or phrases such as “expect” and “intend” or the negative version of those words or other comparable words or phrases of a future or forward-looking nature. These statements relate to the offering of shares of the Series G Preferred Stock, the anticipated use of the net proceeds by Medallion Bank and the grant to the underwriters of an option to purchase additional shares of the Series G Preferred Stock. No assurance can be given that Medallion Bank will decide to redeem its Series E Preferred Stock or, if it does, the amount to be redeemed and the timing of redemption and required regulatory approval. Medallion Bank undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. For a description of certain risks to which Medallion Bank is or may be subject, please refer to the factors discussed under the headings “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors,” in Medallion Bank’s Annual Report on Form 10-K for the year ended December 31, 2025 and Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026 and June 30, 2026.

This press release does not constitute a notice of redemption with respect to the Series E Preferred Stock.

Company Contact

Investor Relations
212-328-2176
investorrelations@medallion.com

COMMACK, NY, Sept. 30, 2026 (GLOBE NEWSWIRE) — SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”), a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to patients, physicians and caregivers through the development, commercialization, and distribution of novel specialty products that address unmet market needs, today announced that it has determined to effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-25. The reverse stock split is expected to take effect before markets open on Monday, October 5, 2026. The Company’s common stock will continue to be traded on the Nasdaq Capital Market under the symbol “SCNX” and will begin trading on a split-adjusted basis when the market opens on Monday, October 5, 2026. The new CUSIP number for the Company’s common stock following the reverse stock split will be 80880X203. As of September 30, 2026, the Company has 41,064,146 shares of common stock issued and outstanding. Following the reverse stock split, the Company expects to have approximately 1,642,565 shares of common stock issued and outstanding.

The reverse stock split is intended to enable the Company to achieve several important corporate objectives, including enabling the Company to maintain compliance with the minimum bid price requirement under Nasdaq’s continued listing criteria and making additional shares of common stock available for future issuance.

At the effective time of the reverse stock split, every 25 shares of the Company’s issued and outstanding common stock will be converted automatically into one issued and outstanding share of common stock without any change in the par value per share. Stockholders holding shares through a brokerage account will have their shares automatically adjusted to reflect the 1-for-25 reverse stock split. The reverse split will not result in any change in the par value per share or the total number of authorized shares of common stock.

The reverse stock split will affect all stockholders uniformly and will not alter any stockholder’s percentage interest in the Company’s equity, except to the extent that the reverse stock split would result in a stockholder owning a fractional share. No fractional shares will be issued in connection with the reverse stock split. Stockholders of record otherwise entitled to receive a fractional shares as a result of the reverse stock split will receive a cash payment in lieu of such fractional share. Proportional adjustments will be made to the number of shares of the Company’s common stock issuable upon exercise or conversion of the Company’s equity awards, convertible preferred stock and warrants, as well as the applicable exercise or conversion price. Stockholders with shares in brokerage accounts should direct any questions concerning the reverse stock split to their broker; all other stockholders may direct questions to the Company’s transfer agent, Continental Stock Transfer & Trust Company.

About Scienture Holdings, Inc.

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), through its wholly owned subsidiary, Scienture, LLC, is a comprehensive pharmaceutical product company focused on providing enhanced value to patients, physicians and caregivers by offering novel specialty products to satisfy unmet market needs. Scienture, LLC is a branded, specialty pharmaceutical company consisting of a highly experienced team of industry professionals who are passionate about developing and bringing to market unique specialty products that provide enhanced value to patients and healthcare systems. The assets in development at Scienture are across therapeutics areas, indications and cater to different market segments and channels. For more information please visit: www.scientureholdings.com and www.scienture.com.

Cautionary Statements Regarding Forward-Looking Statements

This press release contains certain statements that may be deemed to be “forward-looking statements” within the federal securities laws, including the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Statements that are not historical are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements relate to future events or our future performance or future financial condition. These forward-looking statements are not historical facts, but rather are based on current expectations, estimates and projections about our company, our industry, our beliefs and our assumptions. Such forward-looking statements include, but are not limited to, statements regarding our or our management team’s expectations, hopes, beliefs, intentions or strategies regarding the future, including for the intended reverse stock split and the products we may launch, the success those products may have in the marketplace, and our strategies related to those products. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” or the negative of these terms or other similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are subject to a number of risks and uncertainties (some of which are beyond our control) that may cause actual results or performance to be materially different from those expressed or implied by such forward-looking statements. Accordingly, readers should not place undue reliance on any forward-looking statements. These risks include risks relating to agreements with third parties; our ability to raise funding in the future, as needed, and the terms of such funding, including potential dilution caused thereby; our ability to continue as a going concern; security interests under certain of our credit arrangements; our ability to maintain the listing of our common stock on The Nasdaq Stock Market LLC; claims relating to alleged violations of intellectual property rights of others; the outcome of any current legal proceedings or future legal proceedings that may be instituted against us; unanticipated difficulties or expenditures relating to our business plan; and those risks detailed in our most recent Annual Report on Form 10-K, as amended, and subsequent reports filed with the Securities and Exchange Commission.

Forward-looking statements speak only as of the date they are made. Scienture Holdings, Inc. undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise that occur after that date, except as otherwise provided by law.

Contact:

SCIENTURE HOLDINGS, INC.
20 Austin Blvd
Commack, NY 11725
Email: IR@Scienture.com

HAMILTON, Bermuda, Sept. 30, 2026 (GLOBE NEWSWIRE) — American Overseas Group Limited (BSX: AORE.BH) (Pink Sheets: AOREF.PK) (“AOG” or the “Company”) today reported consolidated net income available to common shareholders of $1.6 million, or $33.60 per diluted share, for the three months ended June 30, 2026. This compares to consolidated net income available to common shareholders of $2.5 million, or $53.51 per diluted share, for the three months ended June 30, 2025. Book value per weighted share at June 30, 2026 was $1,338.04, an increase from the book value per weighted share of $1,139.67 at June 30, 2025.

For the three months ended June 30, 2026, net earned property and casualty premiums decreased $1.3 million from $12.8 million a year ago to $11.5 million.   

Quarter to Date fee income decreased $0.4 million from $5.4 million to $5.0 million and gross written premiums decreased $10.0 million, moving from $260.9 million to $250.9 million. Quarter to Date Loss and loss adjustment expenses as a percentage of earned premium increased from 58.3% to 63.3%.  

For the three months ended June 30, 2026, operating expenses increased $0.2 million from $3.3 million to $3.5 million.

As part of its ongoing capital management efforts, the Company will continue to redirect excess capital within the group to debt reduction. The Company reduced the outstanding principal balance of its 12% Senior Secured Notes by $6.5 million in the first half of 2026, reducing the balance of its 12% Notes to $4.1 million as of June 30, 2026, and reducing total outstanding debt to a balance of $9.4 million as of June 30, 2026. Additionally, the Company retired the remaining outstanding principal balance of its 12% Senior Secured Notes in the 3rd quarter of 2026, reducing total outstanding debt to a balance of $5.3 million, which is comprised of its 9% Series A Senior Secured Notes. The Company expects to take additional steps towards leverage reduction, followed by returned value to shareholders unless more compelling opportunities arise.

Forward-Looking Statements

This release contains statements that may be considered “forward-looking statements” within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include, without limitation, the Company’s expectations respecting the volatility of its insured portfolio, losses, loss reserves and loss development, the adequacy and availability of its liquidity and capital resources, its current run off strategy, its strategy for writing other reinsurance businesses and its expense reduction measures. These statements are based on current expectations and the current views of the economic and operating environment and are not guarantees of future performance. A number of risks and uncertainties, including economic competitive conditions, could cause actual results to differ materially from those projected in forward-looking statements. The Company’s actual results could differ materially from those expressed or implied in the forward-looking statements.

Information About the Company

American Overseas Group Limited is an insurance holding company incorporated in Bermuda and a tax resident of the United Kingdom. Its operating subsidiaries provide specialty property/casualty insurance, reinsurance and insurance management services. More information can be found at www.aoreltd.com.

American Overseas Group Limited

info@aoreltd.com

American Overseas Group Limited  
Consolidated Balance Sheets  
(unaudited)  
As of June 30, 2026 and December 31, 2025  
(dollars in thousands)  
                           
                June 30, 2026     December 31, 2025    
Assets                    
                           
    Investments:                
      Fixed-maturity securities held as available for sale, at fair value   $ 153,356       $ 161,312      
      Equity investments held as available for sale, at fair value       1,053         1,041      
    Cash and cash equivalents       54,331         45,140      
    Restricted cash       1,691         843      
    Accrued investment income       1,163         1,135      
    Premiums receivable       212,973         211,993      
    Deferred insurance premiums       320,614         299,720      
    Reinsurance balances receivable, net       491,282         481,444      
    Deferred policy acquisition costs       9,056         9,420      
    Intangible assets       4,800         4,800      
    Goodwill         33,050         33,050      
    Other assets       6,545         5,373      
      Total Assets     $ 1,289,914       $ 1,255,271      
                           
Liabilities and Equity                
                           
  Liabilities:                
    Loss and loss expense reserve     $ 475,640       $ 465,401      
    Deferred commission income       6,083         6,481      
    Unearned premiums       332,231         311,073      
    Ceded premium payable       235,087         233,727      
    Payable to general agents       309         459      
    Funds withheld       133,397         133,343      
    Accounts payable and accrued liabilities       30,462         26,472      
    Notes payable       9,360         15,833      
    Non-owned interest in VIE       300         300      
    Interest payable       119         435      
    Deferred tax liability       4,066         3,413      
      Total Liabilities       1,227,054         1,196,937      
                           
  Shareholders’ Equity:                
    Common shares       4,698         4,698      
    Additional paid-in capital       189,206         189,179      
    Accumulated other comprehensive income (loss)       (2,292 )       (1,932 )    
    Retained deficit       (128,752 )       (133,611 )    
      Total Shareholders’ Equity       62,860         58,334      
                           
      Total Liabilities and Equity     $ 1,289,914       $ 1,255,271      
                           
    See Notes to June 30, 2026 Consolidated Financial Statements available on American Overseas Group Ltd. Website at www.aoreltd.com  
                           
  American Overseas Group Limited  
  Consolidated Statements of Operations  
  (unaudited)  
  (dollars in thousands, except share and per share amounts)  
                                 
                  Three months ended June 30,   Six months ended June 30,  
                    2026       2025   2026       2025    
    Revenues                      
                                 
      Net premiums earned     $ 11,533     $ 12,783     $ 23,263     $ 26,136    
      Fee income       4,985       5,386       11,596       11,802    
      Net investment income       544       472       1,014       962    
      Net realized gains on investments       –       (6 )     (75 )     (6 )  
      Other income       17       38       21       53    
                                 
        Total revenues       17,079       18,673       35,819       38,947    
                                 
    Expenses                      
      Losses and loss adjustment expenses       7,298       7,455       13,777       14,506    
      Acquisition expenses       3,831       4,052       7,689       8,125    
      Operating expenses       3,519       3,294       7,284       6,415    
      Interest expense       333       578       768       1,157    
                                 
        Total expenses       14,981       15,379       29,518       30,203    
                                 
                                 
  Pre-tax net profit (loss)     $ 2,098     $ 3,294     $ 6,301     $ 8,744    
      Income tax (expense)       (520 )     (780 )     (1,442 )     (1,977 )  
                                 
  Net profit (loss) available to common shareholders       1,578       2,514       4,859       6,767    
                                 
    Net profit (loss) per common share:                    
    Basic         $ 33.60     $ 53.51     $ 103.41     $ 144.04    
    Diluted           33.60       53.51       103.41       144.04    
                                 
    Weighted-average number of common shares outstanding:                  
    Basic           46,979       46,979       46,979       46,979    
    Diluted           46,979       46,979       46,979       46,979    
                                 
  See Notes to June 30, 2026 Consolidated Financial Statements available on American Overseas Group Ltd. Website at www.aoreltd.com  
                                 

MOLINE, Ill., Sept. 30, 2026 (GLOBE NEWSWIRE) — QCR Holdings, Inc. (NASDAQ: QCRH) (“QCRH” or the “Company”) announced today that its third quarter ended September 30, 2026, financial results will be released after the market closes on Tuesday, October 20, 2026. The Company will host a conference call and webcast the next day, Wednesday, October 21, 2026, at 10:00 a.m. Central Time to discuss the results. Shareholders, analysts, and other interested parties are invited to join.

Teleconference
Dial-in information for the call is 888-346-9286 (international 412-317-5253). Participants should request to join the QCR Holdings, Inc. call. The event will be archived and available for replay through October 28, 2026. The replay access information is 855-669-9658 (international 412-317-0088); access code 5670385.

Webcast
A webcast of the teleconference can be accessed at the Company’s News and Events page at www.qcrh.com. An archived version of the webcast will be available at the same location shortly after the live event has ended.

About Us
QCR Holdings, Inc., headquartered in Moline, Illinois, is a relationship-driven, multi-bank holding company serving the Quad Cities, Cedar Rapids, Cedar Valley, Des Moines/Ankeny and Springfield communities through its wholly owned subsidiary banks. The banks provide full-service commercial and consumer banking and trust and wealth management services. Quad City Bank & Trust Company, based in Bettendorf, Iowa, commenced operations in 1994, Cedar Rapids Bank & Trust Company, based in Cedar Rapids, Iowa, commenced operations in 2001, Community State Bank, based in Ankeny, Iowa, was acquired by the Company in 2016, and Guaranty Bank, based in Springfield, Missouri, was acquired by the Company in 2018. Additionally, the Company serves the Waterloo/Cedar Falls, Iowa community through Community Bank & Trust, a division of Cedar Rapids Bank & Trust Company. The Company has 35 locations in Iowa, Missouri, and Illinois. As of June 30, 2026, the Company had $9.5 billion in assets, $7.0 billion in loans and $7.4 billion in deposits. For additional information, please visit the Company’s website at www.qcrh.com.

Contact
Doug Neumann
VP, Investor Relations
(309) 743-7753
dneumann@qcrh.com                                                                 

Clinical trial designed to demonstrate proof-of-concept for soquelitinib in the treatment of hidradenitis suppurativa and evaluate its effects on Th17 biology

SOUTH SAN FRANCISCO, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that enrollment has begun in its Phase 1b clinical trial of soquelitinib for the treatment of patients with hidradenitis suppurativa.

“The initiation of our Phase 1b hidradenitis suppurativa trial provides an important opportunity to expand the potential of soquelitinib to a wider range of diseases,” said Richard A. Miller, M.D., co-founder, president and chief executive officer of Corvus. “In addition to evaluating safety and efficacy, the trial is designed to evaluate soquelitinib’s ability to modulate Th17-driven disease, complementing the results we have already seen in Th2-driven diseases such as atopic dermatitis. Hidradenitis suppurativa is primarily driven by Th17 cells, which we have shown to be reduced in patients with atopic dermatitis treated with soquelitinib. We look forward to exploring the potential of selective ITK inhibition with soquelitinib to provide an oral and potentially more effective treatment option for hidradenitis suppurativa with a novel mechanism of action.”

The Phase 1b clinical trial is designed to enroll up to 25 patients 18 years and older with moderate to severe hidradenitis suppurativa. All patients will receive a soquelitinib dose of 200 mg twice per day for 12 weeks, followed by a 90-day follow-up period with no treatment. The primary endpoint of the trial is safety and tolerability. The key efficacy endpoint is the proportion of patients achieving Hidradenitis Suppurativa Clinical Response (HiSCR) 50/75 at week 12, and the trial will also evaluate skin and blood biomarkers.

This is the fourth indication under clinical development for soquelitinib, which is also in a registrational Phase 3 trial for relapsed/refractory peripheral T cell lymphoma (PTCL), a Phase 2 trial (SIERRA1) for moderate to severe atopic dermatitis (AD), and a Phase 2 trial for autoimmune lymphoproliferative syndrome (ALPS). Corvus also plans to initiate a Phase 2 clinical trial of soquelitinib in patients with asthma later this year.

About Corvus Pharmaceuticals
Corvus Pharmaceuticals is a clinical-stage biopharmaceutical company pioneering the development of ITK inhibition as a new approach to immunotherapy for a broad range of immune diseases and cancer. The Company’s lead product candidate is soquelitinib, an investigational, oral, small molecule drug that selectively inhibits ITK. Soquelitinib is being evaluated in a registrational Phase 3 clinical trial for relapsed/refractory PTCL, a Phase 2 clinical trial for the treatment of atopic dermatitis, and a Phase 1b clinical trial for hidradenitis suppurativa. Its other clinical-stage candidates are being developed for a variety of cancer indications. For more information, visit www.corvuspharma.com or follow the Company on LinkedIn.

About Hidradenitis Suppurativa1
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful lesions such as deep-seated nodules, abscesses, skin tunnels, and fibrotic scars. The condition’s impact extends beyond physical discomfort, with associated pain, drainage, malodor, and scarring often leading to profound negative psychosocial implications for affected individuals. Treatments include topical therapies, oral therapies, systemic injectable biologic therapies, and direct interventions. HS is associated with elevated levels of Th17 cells compared to regulatory T cells (Tregs), leading to high levels of IL-17 and other cytokines that cause inflammation.

About Soquelitinib
Soquelitinib (formerly CPI-818) is an investigational small molecule drug given orally designed to selectively inhibit ITK (interleukin-2-inducible T cell kinase), an enzyme that is expressed predominantly in T cells and plays a role in T cell and natural killer (NK) cell immune function. Soquelitinib has been shown to affect T cell differentiation and induce the generation of Th1 helper cells while blocking the development of both Th2 and Th17 cells and production of their secreted cytokines. Th1 T cells are required for immunity to tumors, viral infections, and other infectious diseases. Th2 and Th17 helper T cells are involved in the pathogenesis of many autoimmune and allergic diseases. Recent studies have demonstrated that ITK controls a switch between the differentiation of Th17 proinflammatory cells and T regulatory suppressor cells. Inhibition of ITK leads to a shift toward T regulatory cell differentiation, which has the potential to suppress autoimmune and inflammatory reactions. The Company believes the inhibition of specific molecular targets in T cells may be of therapeutic benefit for patients with autoimmune and allergic diseases and in cancers, including solid tumors. Based on results from a Phase 1/1b clinical trial in patients with refractory T cell lymphomas (published in Blood), which demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies, the Company is enrolling a registrational Phase 3 clinical trial (NCT06561048) of soquelitinib in patients with relapsed/refractory PTCL. Soquelitinib is also now being investigated in a randomized placebo-controlled Phase 2 clinical trial in patients with atopic dermatitis and a Phase 1b clinical trial in patients with hidradenitis suppurativa. A publication describing the chemistry, enzymology, and biology of soquelitinib appeared in npj Drug Discovery in December 2024 and is available online at the Nature website and on the Publications and Presentations page of the Corvus website.

Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the potential safety, tolerability, clinical benefit, and efficacy of the Company’s product candidates, including soquelitinib; the potential use of soquelitinib to improve therapy for a broad range of patients with T cell lymphoma, atopic dermatitis, hidradenitis suppurativa, other immune diseases, and cancers; and clinical strategy and the design of clinical trials, including the timeline for initiation, target or expected number of patients to be enrolled, dose levels, and other product development milestones. All statements other than statements of historical fact contained in this press release are forward-looking statements. These statements often include words such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” or similar expressions. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, filed with the Securities and Exchange Commission on August 6, 2026, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. In particular, the following factors, among others, could cause results to differ materially from those expressed or implied by such forward-looking statements: the Company’s ability to demonstrate sufficient evidence of efficacy and safety in its clinical trials of its product candidates; the accuracy of the Company’s estimates relating to its ability to initiate and/or complete preclinical studies and clinical trials and release data from such studies and clinical trials; the results of preclinical studies and interim data from clinical trials not being predictive of future results; the Company’s ability to enroll sufficient numbers of patients in its clinical trials; the unpredictability of the regulatory process; regulatory developments in the United States and foreign countries; the costs of clinical trials may exceed expectations; and the Company’s ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the events and circumstances reflected in the forward-looking statements will be achieved or occur, and the timing of events and circumstances and actual results could differ materially from those projected in the forward-looking statements. Accordingly, you should not place undue reliance on these forward-looking statements. All such statements speak only as of the date made, and the Company undertakes no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events, or otherwise.

INVESTOR CONTACT:
Zack Kubow
Vice President, Investor Relations and Corporate Communications
Corvus Pharmaceuticals, Inc.
investors@corvuspharma.com

MEDIA CONTACT:
Julia Stern
Real Chemistry
media@corvuspharma.com

_________________________
1
https://www.ncbi.nlm.nih.gov/books/NBK534867/

LIVERMORE, Calif., Sept. 30, 2026 (GLOBE NEWSWIRE) — FormFactor, Inc. (NASDAQ: FORM), today announced management’s participation in the 18th Annual CEO Investor Summit 2026, being held Tuesday, October 13th at the St. Regis Hotel in San Francisco, California.

The presentation material utilized during the CEO Investor Summit will be made accessible on the events page of the Company’s website at www.formfactor.com.

About the 18th Annual CEO Investor Summit 2026
The CEO Investor Summit is held annually each year during the SEMICON West industry trade show.

Collectively hosted and funded by participating companies, the CEO Investor Summit features a “round-robin” format consisting of small group meetings with company management teams. During the event, investors and analysts will have the opportunity to meet with the majority of the 11 management teams during the small group meeting sessions and networking events.

The 11 management teams collectively hosting the 18th Annual CEO Investor Summit 2026 include: ACM Research (ACMR), Aehr Test Systems (AEHR), Alpha & Omega Semiconductor (AOSL), Cohu, Inc. (COHU), FormFactor (FORM), Ichor Systems (ICHR), InTEST Corporation (INTT), Kulicke & Soffa (KLIC), Photronics (PLAB), QuickLogic (QUIK) and SkyWater Technology (SKYT), an IonQ company (IONQ). B. Riley Securities, Jefferies and Stifel are sponsors of the conference.

Attendance at the CEO Investor Summit is by invitation only and is available solely to accredited investors and publishing research analysts. As space is limited, please RSVP early. Hosts reserve the right to limit attendance as necessary. Last day for registration is October 2, 2026.

RSVP Contacts for 18th Annual CEO Investor Summit 2026
To RSVP for the CEO Investor Summit, please visit the CEO Summit Events website or contact either of the event co-chairs:

Laura J. Guerrant-Oiye
Phone: (808) 960-2642
Email: lauraoiye@gmail.com

Claire E. McAdams
Phone: (530) 265-9899
Email: claire@headgatepartners.com

About FormFactor:

FormFactor, Inc. (NASDAQ: FORM), is a leading provider of essential test and measurement technologies along the full IC life cycle – characterization, modeling, reliability, and design de-bug, to qualification and production test. Semiconductor companies rely upon FormFactor’s products and services to accelerate profitability by optimizing device performance and advancing yield knowledge. The Company serves customers through its network of facilities in Asia, Europe, and North America. For more information, visit the Company’s website at www.formfactor.com.

Source: FormFactor, Inc.

FORM-F

Investor Contact:

Stan Finkelstein
Investor Relations
(925) 290-4321
ir@formfactor.com

AI-driven demand and strong operational execution position Micron for a record fiscal 2027

BOISE, Idaho, Sept. 30, 2026 (GLOBE NEWSWIRE) — Micron Technology, Inc. (Nasdaq: MU) today announced results for its fourth quarter and full year of fiscal 2026, which ended September 3, 2026.

Fiscal Q4 2026 Highlights

    • Revenue of $54.23 billion versus $41.46 billion for the prior quarter and $11.32 billion for the same period last year
    • GAAP net income of $37.70 billion, or $32.87 per diluted share
    • Non-GAAP net income of $38.40 billion, or $33.42 per diluted share
    • Operating cash flow of $43.97 billion versus $25.39 billion for the prior quarter and $5.73 billion for the same period last year

Fiscal 2026 Highlights

    • Revenue of $133.19 billion versus $37.38 billion for the prior year
    • GAAP net income of $84.97 billion, or $74.33 per diluted share
    • Non-GAAP net income of $86.76 billion, or $75.52 per diluted share
    • Operating cash flow of $89.68 billion versus $17.53 billion for the prior year

“Micron delivered record fiscal 2026 results, and we expect an even stronger fiscal 2027,” said Sanjay Mehrotra, Chairman and CEO of Micron Technology. “AI is becoming Super Intelligence (SI), and memory enhances this intelligence and the competitiveness of our customers’ platforms. We are increasing our investments in technology, products and manufacturing to help drive SI forward with our customers, and our Strategic Customer Agreements provide added confidence in the durability of Micron’s financial performance.”

Quarterly Financial Results
(in millions, except per share amounts) GAAP(1)   Non-GAAP(2)
FQ4-26 FQ3-26 FQ4-25   FQ4-26 FQ3-26 FQ4-25
               
Revenue $ 54,229   $ 41,456   $ 11,315     $ 54,229   $ 41,456   $ 11,315  
Gross margin   47,047     35,056     5,054       47,204     35,199     5,169  
Percent of revenue   86.8 %   84.6 %   44.7 %     87.0 %   84.9 %   45.7 %
Operating expenses   3,296     1,738     1,400       2,568     1,518     1,214  
Operating income   43,751     33,318     3,654       44,636     33,681     3,955  
Percent of revenue   80.7 %   80.4 %   32.3 %     82.3 %   81.2 %   35.0 %
Net income   37,701     28,243     3,201       38,398     28,857     3,469  
Diluted earnings per share   32.87     24.67     2.83       33.42     25.11     3.03  

Annual Financial Results
(in millions, except per share amounts) GAAP(1)   Non-GAAP(2)
FY-26 FY-25   FY-26 FY-25
           
Revenue $ 133,188   $ 37,378     $ 133,188   $ 37,378  
Gross margin   107,504     14,873       108,032     15,286  
Percent of revenue   80.7 %   39.8 %     81.1 %   40.9 %
Operating expenses   8,164     5,103       6,841     4,440  
Operating income   99,340     9,770       101,191     10,846  
Percent of revenue   74.6 %   26.1 %     76.0 %   29.0 %
Net income   84,969     8,539       86,758     9,470  
Diluted earnings per share   74.33     7.59       75.52     8.29  

Investments in capital expenditures, net(2) were $10.77 billion for the fourth quarter of 2026 and $27.37 billion for the full year of 2026. Adjusted free cash flow(2) was $33.20 billion for the fourth quarter of 2026 and $62.31 billion for the full year of 2026. Micron ended the year with cash, marketable investments, and restricted cash of $73.48 billion. On September 30, 2026, Micron’s Board of Directors declared a quarterly dividend of $0.15 per share, payable in cash on October 29, 2026, to shareholders of record as of the close of business on October 14, 2026.

Quarterly Business Unit Financial Results
  FQ4-26 FQ3-26 FQ4-25
       
Cloud Memory Business Unit      
Revenue $ 16,283   $ 13,769   $ 4,543  
Gross margin   83 %   83 %   59 %
Operating margin   76 %   78 %   48 %
       
Core Data Center Business Unit      
Revenue $ 18,002   $ 11,524   $ 1,577  
Gross margin   90 %   87 %   41 %
Operating margin   85 %   83 %   25 %
       
Mobile and Client Business Unit      
Revenue $ 13,114   $ 11,521   $ 3,760  
Gross margin   90 %   87 %   36 %
Operating margin   88 %   86 %   29 %
       
Automotive and Embedded Business Unit      
Revenue $ 6,824   $ 4,634   $ 1,434  
Gross margin   84 %   79 %   31 %
Operating margin   79 %   75 %   20 %


Business Outlook

The following table presents Micron’s guidance for the first quarter of 2027:

FQ1-27 GAAP(1) Outlook Non-GAAP(2) Outlook
     
Revenue $61.5 billion ± $1.5 billion $61.5 billion ± $1.5 billion
Gross margin Approximately 85.95% Approximately 86.25%
Operating expenses Approximately $2.31 billion Approximately $2.06 billion
Diluted earnings per share $37.84 ± $1.00 $38.15 ± $1.00

Further information regarding Micron’s business outlook is included in the prepared remarks and slides, which have been posted at investors.micron.com.

Product Highlights

  • We began sampling the industry’s first 512GB ultra dense high-capacity DDR5 RDIMM modules capable of speeds up to 9,200 MT/s.
  • We have completed multiple customer qualifications of our 1-gamma based, 8,800 MT/s high-speed server RDIMM modules.
  • Our industry leading server LPDDR SOCAMM portfolio revenue more than doubled sequentially in the fourth quarter of 2026.
  • Our 7600 PCIe Gen 5 and 9650 PCIe Gen 6 SSD high-performance products are now shipping to market-leading customers for KV-cache applications.
  • Our 6600 ION SSD achieved a strong volume ramp in the fourth quarter of 2026.
  • We are now shipping 6-channel 1-gamma LPDDR5X for flagship mobile devices.
  • We have secured design wins with every Tier 1 OEM customer for AI workstation product.
  • Our 4600 SSD secured additional qualifications with leading PC OEMs.
  • We began sampling 1-gamma based LPDDR6 products to multiple physical AI markets.

Investor Webcast

Micron will host a conference call on Wednesday, September 30, 2026 at 2:30 p.m. Mountain Time to discuss its fourth-quarter and full-year financial results and provide forward-looking guidance for its first quarter. A live webcast of the call will be available online at investors.micron.com. A webcast replay will be available for one year after the call.

We encourage you to visit our website at micron.com throughout the quarter for the most current information on the company, including information on financial conferences that we may be attending. You can also follow us on LinkedIn, X (@MicronTech) and YouTube (@MicronTechnology).

About Micron Technology, Inc.

Micron Technology, Inc. is a global leader in semiconductor memory and storage, powering AI and compute-intensive applications from cloud to edge. With a relentless focus on our customers, technology and product leadership, and manufacturing and operational excellence, Micron’s comprehensive portfolio of high-performance DRAM, NAND and NOR solutions deliver the speed, efficiency, and scale today’s workloads demand, accelerating intelligence to enrich life for all. To learn more about Micron Technology, Inc. (Nasdaq: MU), visit micron.com.

© 2026 Micron Technology, Inc. All rights reserved. Micron, the Micron logo, and all other Micron trademarks are the property of Micron Technology, Inc. All other trademarks are the property of their respective owners.

Forward-Looking Statements

This press release contains forward-looking statements regarding our industry, our strategic position, our customers, including customer demand, our investments and the goals for such investments, our business opportunity, our products and technology, and our financial and operating performance, including our guidance for the first quarter. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially. Please refer to the documents we file with the Securities and Exchange Commission, including our most recent Form 10-K and Form 10-Q. These documents contain and identify important factors that could cause our actual results to differ materially from those contained in these forward-looking statements. These certain factors can be found at investors.micron.com/risk-factor. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. We are under no duty to update any of the forward-looking statements to conform these statements to actual results.

(1) GAAP represents U.S. Generally Accepted Accounting Principles.
(2) Non-GAAP represents GAAP excluding the impact of certain activities, which management excludes in analyzing our operating results and understanding trends in our earnings; adjusted free cash flow; investments in capital expenditures, net; and business outlook. Further information regarding Micron’s use of non-GAAP measures and reconciliations between GAAP and non-GAAP measures are included within this press release.

MICRON TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In millions, except per share amounts)
(Unaudited)

  4th Qtr. 3rd Qtr. 4th Qtr. Year Ended
  September 3,
2026
May 28,
2026
August 28,
2025
September 3,
2026
August 28,
2025
           
Revenue $ 54,229   $ 41,456   $ 11,315   $ 133,188   $ 37,378  
Cost of goods sold   7,182     6,400     6,261     25,684     22,505  
Gross margin   47,047     35,056     5,054     107,504     14,873  
           
Research and development   1,913     1,316     1,047     5,650     3,798  
Selling, general, and administrative   859     407     314     1,947     1,205  
Other operating (income) expense, net   524     15     39     567     100  
Operating income   43,751     33,318     3,654     99,340     9,770  
           
Interest income   575     215     146     1,084     496  
Interest expense   —     —     (124 )   (106 )   (477 )
Other non-operating income (expense), net   (88 )   (321 )   (45 )   (647 )   (135 )
    44,238     33,212     3,631     99,671     9,654  
           
Income tax (provision) benefit   (6,583 )   (4,978 )   (429 )   (14,761 )   (1,124 )
Equity in net income (loss) of equity method investees   46     9     (1 )   59     9  
Net income $ 37,701   $ 28,243   $ 3,201   $ 84,969   $ 8,539  
           
Earnings per share          
Basic $ 33.36   $ 25.03   $ 2.86   $ 75.38   $ 7.65  
Diluted   32.87     24.67     2.83     74.33     7.59  
           
Number of shares used in per share calculations          
Basic   1,130     1,128     1,120     1,127     1,116  
Diluted   1,147     1,145     1,131     1,143     1,125  

MICRON TECHNOLOGY, INC.
CONSOLIDATED BALANCE SHEETS
(In millions)
(Unaudited)

As of September 3,
2026
May 28,
2026
August 28,
2025
       
Assets      
Cash and equivalents $ 38,364   $ 24,995   $ 9,642  
Short-term investments   5,070     1,027     665  
Receivables   36,197     31,025     9,265  
Inventories   10,372     8,567     8,355  
Other current assets   1,067     1,123     914  
Total current assets   91,070     66,737     28,841  
Long-term marketable investments   30,019     4,106     1,629  
Property, plant, and equipment   63,310     56,426     46,590  
Goodwill   1,150     1,150     1,150  
Other noncurrent assets   10,339     5,693     4,588  
Total assets $ 195,888   $ 134,112   $ 82,798  
       
Liabilities and equity      
Accounts payable and accrued expenses $ 22,605   $ 15,521   $ 9,649  
Current debt   491     582     560  
Other current liabilities   4,386     3,385     1,245  
Total current liabilities   27,482     19,488     11,454  
Long-term debt   4,688     5,140     14,017  
Noncurrent unearned government incentives   786     1,020     1,018  
Noncurrent customer contract liabilities   12,895     568     142  
Other noncurrent liabilities   11,659     7,172     2,002  
Total liabilities   57,510     33,388     28,633  
       
Commitments and contingencies      
       
Shareholders’ equity      
Common stock   128     128     127  
Additional capital   14,974     14,442     13,339  
Retained earnings   131,851     94,682     48,583  
Treasury stock   (8,502 )   (8,502 )   (7,852 )
Accumulated other comprehensive income (loss)   (73 )   (26 )   (32 )
Total equity   138,378     100,724     54,165  
Total liabilities and equity $ 195,888   $ 134,112   $ 82,798  

MICRON TECHNOLOGY, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
(Unaudited)

For the year ended September 3,
2026
August 28,
2025
     
Cash flows from operating activities    
Net income $ 84,969   $ 8,539  
Adjustments to reconcile net income to net cash provided by operating activities:    
Depreciation expense and amortization of intangible assets   9,503     8,352  
Stock-based compensation   1,333     972  
Change in operating assets and liabilities:    
Receivables   (25,206 )   (1,776 )
Inventories   (2,017 )   520  
Accounts payable and accrued expenses   8,707     862  
Other current liabilities   3,141     (272 )
Other noncurrent liabilities   9,633     381  
Other   (388 )   (53 )
Net cash provided by operating activities   89,675     17,525  
     
Cash flows from investing activities    
Purchases of available-for-sale securities   (34,871 )   (1,890 )
Expenditures for property, plant, and equipment   (30,712 )   (15,857 )
Purchases of non-marketable equity securities   (1,046 )   (34 )
Proceeds from government incentives   3,316     2,005  
Proceeds from maturities and sales of available-for-sale securities   1,988     1,698  
Other   (316 )   (9 )
Net cash used for investing activities   (61,641 )   (14,087 )
     
Cash flows from financing activities    
Proceeds from customer contract liability deposits   12,747     —  
Proceeds from issuance of debt   —     4,430  
Repayments of debt   (10,043 )   (4,619 )
Repurchases of common stock – withholdings on employee equity awards   (1,127 )   (340 )
Repurchases of common stock – repurchase program   (650 )   —  
Payments of dividends to shareholders   (610 )   (522 )
Other   313     201  
Net cash provided by (used for) financing activities   630     (850 )
     
Effect of changes in currency exchange rates on cash, cash equivalents, and restricted cash   81     6  
     
Net increase in cash, cash equivalents, and restricted cash   28,745     2,594  
Cash, cash equivalents, and restricted cash at beginning of period   9,646     7,052  
Cash, cash equivalents, and restricted cash at end of period $ 38,391   $ 9,646  

MICRON TECHNOLOGY, INC.
RECONCILIATION OF GAAP TO NON-GAAP MEASURES
(In millions, except per share amounts)

  4th Qtr. 3rd Qtr. 4th Qtr. Year Ended
  September 3,
2026
May 28,
2026
August 28,
2025
September 3,
2026
August 28,
2025
           
GAAP gross margin $ 47,047   $ 35,056   $ 5,054   $ 107,504   $ 14,873  
Stock-based compensation   157     143     115     528     409  
Other   —     —     —     —     4  
Non-GAAP gross margin $ 47,204   $ 35,199   $ 5,169   $ 108,032   $ 15,286  
           
GAAP operating expenses $ 3,296   $ 1,738   $ 1,400   $ 8,164   $ 5,103  
Stock-based compensation   (207 )   (198 )   (147 )   (754 )   (566 )
Patent license charges   (500 )   —     —     (500 )   (57 )
Other   (21 )   (22 )   (39 )   (69 )   (40 )
Non-GAAP operating expenses $ 2,568   $ 1,518   $ 1,214   $ 6,841   $ 4,440  
           
GAAP operating income $ 43,751   $ 33,318   $ 3,654   $ 99,340   $ 9,770  
Stock-based compensation   364     341     262     1,282     975  
Patent license charges   500     —     —     500     57  
Other   21     22     39     69     44  
Non-GAAP operating income $ 44,636   $ 33,681   $ 3,955   $ 101,191   $ 10,846  
           
GAAP net income $ 37,701   $ 28,243   $ 3,201   $ 84,969   $ 8,539  
Stock-based compensation   364     341     262     1,282     975  
Patent license charges   500     —     —     500     57  
Loss on debt prepayments   9     325     9     511     59  
Other   22     23     39     50     40  
Estimated tax effects of above and other tax adjustments   (198 )   (75 )   (42 )   (554 )   (200 )
Non-GAAP net income $ 38,398   $ 28,857   $ 3,469   $ 86,758   $ 9,470  
           
GAAP weighted-average common shares outstanding – Diluted   1,147     1,145     1,131     1,143     1,125  
Adjustment for stock-based compensation   2     4     14     6     18  
Non-GAAP weighted-average common shares outstanding – Diluted   1,149     1,149     1,145     1,149     1,143  
           
GAAP diluted earnings per share $ 32.87   $ 24.67   $ 2.83   $ 74.33   $ 7.59  
Effects of the above adjustments   0.55     0.44     0.20     1.19     0.70  
Non-GAAP diluted earnings per share $ 33.42   $ 25.11   $ 3.03   $ 75.52   $ 8.29  

RECONCILIATION OF GAAP TO NON-GAAP MEASURES, Continued
  4th Qtr. 3rd Qtr. 4th Qtr. Year Ended
  September 3,
2026
May 28,
2026
August 28,
2025
September 3,
2026
August 28,
2025
           
GAAP net cash provided by operating activities $ 43,973   $ 25,388   $ 5,730   $ 89,675   $ 17,525  
           
Expenditures for property, plant, and equipment   (11,110 )   (7,826 )   (5,658 )   (30,712 )   (15,857 )
Proceeds from sales of property, plant, and equipment   9     9     20     29     48  
Proceeds from government incentives   327     733     711     3,316     2,005  
Investments in capital expenditures, net   (10,774 )   (7,084 )   (4,927 )   (27,367 )   (13,804 )
Adjusted free cash flow $ 33,199   $ 18,304   $ 803   $ 62,308   $ 3,721  

The tables above reconcile GAAP to non-GAAP measures of gross margin, operating expenses, operating income, net income, diluted shares, diluted earnings per share, and adjusted free cash flow. The non-GAAP adjustments above may or may not be infrequent or nonrecurring in nature, but are a result of periodic or non-core operating activities. We believe this non-GAAP information is helpful in understanding trends and in analyzing our operating results and earnings. We are providing this information to investors to assist in performing analysis of our operating results. When evaluating performance and making decisions on how to allocate our resources, management uses this non-GAAP information and believes investors should have access to similar data when making their investment decisions. We believe these non-GAAP financial measures increase transparency by providing investors with useful supplemental information about the financial performance of our business, enabling enhanced comparison of our operating results between periods and with peer companies. The presentation of these adjusted amounts varies from amounts presented in accordance with U.S. GAAP and therefore may not be comparable to amounts reported by other companies. Our management excludes the following items as applicable in analyzing our operating results and understanding trends in our earnings:

  • Stock-based compensation;
  • Gains and losses from settlements;
  • Gains and losses from debt prepayments;
  • Restructure and asset impairments; and
  • The estimated tax effects of above, non-cash changes in net deferred income taxes, assessments of tax exposures, certain tax matters related to prior fiscal periods, and significant changes in tax law. The divergence between our GAAP and non-GAAP income tax (provision) benefit relates to the difference in our GAAP and non-GAAP estimated annual effective tax rates, which are computed separately.

Non-GAAP diluted shares are adjusted for the impact of additional shares resulting from the exclusion of stock-based compensation from non-GAAP income.

MICRON TECHNOLOGY, INC.
RECONCILIATION OF GAAP TO NON-GAAP OUTLOOK

FQ1-27 GAAP Outlook   Adjustments   Non-GAAP Outlook
                 
Revenue $61.5 billion ± $1.5 billion   —         $61.5 billion ± $1.5 billion
Gross margin Approximately 85.95%   0.30 %   A   Approximately 86.25%
Operating expenses Approximately $2.31 billion   $253 million   B   Approximately $2.06 billion
Diluted earnings per share(1) $37.84 ± $1.00   $0.31   A, B, C   $38.15 ± $1.00

Non-GAAP Adjustments
(in millions)
 
     
A Stock-based compensation – cost of goods sold $ 174  
B Stock-based compensation – research and development   166  
B Stock-based compensation – selling, general, and administrative   87  
C Tax effects of the above items and other tax adjustments   (65 )
    $ 362  

(1) GAAP earnings per share and non-GAAP earnings per share based on approximately 1.15 billion diluted shares.

The tables above reconcile our GAAP to non-GAAP guidance based on the current outlook. The guidance does not incorporate the impact of any potential business combinations, divestitures, additional restructuring activities, balance sheet valuation adjustments, strategic investments, financing transactions, and other significant transactions. The timing and impact of such items are dependent on future events that may be uncertain or outside of our control.

CONTACT: Contacts:

Satya Kumar
Investor Relations
satyakumar@micron.com
(408) 450-6199

Mark Plungy
Media Relations
mplungy@micron.com
(408) 203-2910

BOSTON HEIGHTS, Ohio, Sept. 30, 2026 (GLOBE NEWSWIRE) — Arhaus, Inc. (“Arhaus” or the “Company”) (NASDAQ: ARHS), a premium home furnishing brand known for responsibly sourced, artisan-crafted products and heirloom-quality design, today announced the appointment of K.C. Moss as the Company’s first Chief Digital Officer, effective September 30, 2026. Moss will report directly to John Reed, Founder and Chief Executive Officer, and join the Company’s executive leadership team.

The creation of the Chief Digital Officer role reflects Arhaus’ focus on accelerating eCommerce growth, expanding the reach of its brand, and creating new and inspiring ways for clients to discover and engage with Arhaus. In this newly created role, Moss will lead the Company’s digital strategy, with responsibility for eCommerce, digital product and experience, personalization, and client data and analytics.

“Over the past 40 years, we have built a differentiated luxury home furnishings brand around beautiful, artisan-crafted product, and an exceptional client experience,” said John Reed, Founder and Chief Executive Officer. “As Arhaus continues to grow and reach more clients, we believe the opportunity ahead is significant. Digital will be an important part of how we build on our strengths, deepen client relationships, and capture that opportunity.”

Moss brings more than 25 years of experience building and leading digital businesses, with deep expertise across eCommerce, digital product, customer experience, personalization, digital merchandising, and omnichannel capabilities. Her experience building and scaling digital businesses will be instrumental as Arhaus accelerates its eCommerce growth and expands its reach.

“Arhaus has built a truly distinctive brand around beautiful, artisan-crafted product, and an omni-luxury client experience,” said K.C. Moss, Chief Digital Officer. “I am excited to build on that strength by creating more seamless and inspiring ways for clients and design professionals to engage with Arhaus, broaden our reach, and deepen client relationships.”

About Arhaus

Founded in 1986 by Chief Executive Officer John Reed and his father, Arhaus is a premium home furnishings brand built on a simple idea: furniture and décor should be responsibly sourced, lovingly made, and built to last. Arhaus operates a vertically integrated model, designing and sourcing products directly from skilled artisans and carefully selected manufacturing partners around the world, including domestic upholstery production at its own North Carolina manufacturing facility. This approach enables Arhaus to offer a highly exclusive and customizable assortment of heirloom-quality furniture and décor designed to be used and enjoyed for generations.

With more than 100 Showroom locations across the United States, Arhaus’ integrated omni-channel model connects every client touchpoint, from Showroom and interior design to eCommerce and catalog, allowing Arhaus to meet clients wherever and however they choose to shop while delivering a highly personalized client-first experience from discovery through delivery.

For more information, please visit www.arhaus.com.

Investor Contact

Tara Atwood Saja
Vice President, Head of Investor Relations
(440) 439-7700
invest@arhaus.com

LITTLE ROCK, Ark., Sept. 30, 2026 (GLOBE NEWSWIRE) — Bank OZK (the “Bank”) (Nasdaq: OZK) expects to report its third quarter 2026 earnings after the market closes on Tuesday, October 20, 2026. The earnings release, financial supplement and Management Comments on the third quarter of 2026 will be made available simultaneously on the Bank’s investor relations website.   

Management will conduct a conference call to take questions at 7:30 a.m. CT (8:30 a.m. ET) on Wednesday, October 21, 2026. Interested parties may access the conference call live via webcast on the Bank’s investor relations website, or may participate via telephone by registering using this online form. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN that can be used to access the call. A replay of the conference call webcast will be archived on the Bank’s website for at least 30 days.

GENERAL INFORMATION
Bank OZK (Nasdaq: OZK) is a regional bank providing innovative financial solutions delivered by expert bankers with a relentless pursuit of excellence. Established in 1903, Bank OZK conducts banking operations in 267 offices in nine states including Arkansas, Georgia, Florida, Texas, North Carolina, Tennessee, New York, California and Mississippi and had $41.7 billion in total assets as of June 30, 2026. For more information, visit ozk.com.

   
Investor Relations Contact: Jay Staley (501) 906-7842
Media Contact: Michelle Rossow (501) 906-3922

Conference call and webcast to be held at 8:00 a.m. ET on Oct. 1, 2026

BOSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) — Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live conference call and webcast on Thursday, October 1, at 8:00 a.m. ET. The webcast presentation will review clinical results from the GFORCE-1 Phase 1 study of the NEK7-directed MGD MRT-8102 in subjects with elevated cardiovascular disease (CVD) risk. The presentation will include safety and activity data for MRT-8102 across multiple dose levels following 4 weeks of treatment and will showcase pioneering data on the modulation of multiple pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) by MRT-8102.

A webcast of the presentation will be accessible via the “Events & Presentations” section of Monte Rosa’s website at ir.monterosatx.com. Registration for the conference call is available at the following link. An archived version of the webcast will be made available for 30 days following the presentation.

About Monte Rosa
Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monte Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology, and proteomics to rationally design MGDs with unprecedented selectivity. Monte Rosa has developed the industry’s leading pipeline of first-in-class and only-in-class MGDs, spanning autoimmune and inflammatory diseases, oncology, and beyond, with three programs in the clinic. Monte Rosa has ongoing collaborations with leading pharmaceutical companies in the areas of immunology, oncology, and neurology. For more information, visit www.monterosatx.com.

Investors
Andrew Funderburk
ir@monterosatx.com

Media
Cory Tromblee, Scient PR
media@monterosatx.com

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.